Phase I Trial Evaluating Genetically Modified Autologous T Cells Expressing a T-Cell Receptor Recognizing a Cancer/Germline Antigen in Patients With Squamous Cell Non-small Cell Lung Cancer or Head and Neck Squamous Cell Carcinoma
Phase of Trial: Phase I
Latest Information Update: 29 Sep 2017
At a glance
- Drugs IMA-201 (Primary) ; Aldesleukin; Cyclophosphamide; Fludarabine
- Indications Head and neck cancer; Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions
- Acronyms ACTengine
- Sponsors Immatics US
- 26 Sep 2017 Status changed from not yet recruiting to recruiting.
- 05 Sep 2017 Planned initiation date changed from 31 Aug 2017 to 30 Sep 2017.
- 16 Aug 2017 New trial record